Modeling the impact of prioritizing first or second vaccine doses during the 2022 mpox

outbreak

Authors: Patrick A. Clay[1], Emily D. Pollock[1], Enrique Saldariagga[1], Preeti Pathela[2], Michelle

Macaraig[3], Jane R. Zucker[4,5], Bindy Crouch[4], Ian Kracalik[6], Sevgi O. Aral[1], Ian H. Spicknall[1]

[1]CDC, National Center for HIV, Hepatitis, STD, and Tuberculosis Prevention, Division of STD

Prevention

[2]New York City Department of Health and Mental Hygiene, Bureau of Hepatitis, HIV, and STI

[3]New York City Department of Health and Mental Hygiene, Bureau of Tuberculosis Control

[4]New York City Department of Health and Mental Hygiene, Bureau of Immunization

[5]CDC, National Center for Influenza and Respiratory Diseases, Immunization Services Division

[6]CDC, National Center for Emerging & Zoonotic Infectious Diseases, Division of High Consequence

Pathogens and Pathology

Abstract

Background: Early in the 2022 mpox outbreak, vaccine doses and administrative capacity were limited. The US recommendation was to administer two doses of the JYNNEOS® vaccine 4 weeks apart. However, because of the limited vaccine supply and high demand, New York City (NYC) prioritized administration of first doses to reach a larger portion of the impacted population as quickly as possible. We estimated mpox cases averted compared to strategies that prioritized 2-dose vaccination for a smaller portion of the population.

Methods: We fit a dynamic network transmission model to incident mpox cases reported by NYC, as well as to first and second vaccine doses administered from May 2022 through March 2023. Model output consisted of predicted cases over time when vaccine doses were administered with the 'first-dose priority' strategy, compared with counterfactual simulations where individuals were either pre-allocated full courses of the vaccine ('second-dose priority' strategy), or not pre-allocated doses, but where doses were administered to those eligible for a second dose ahead of those waiting for a first dose ('intermediate' strategy).

Results: We estimate that NYC's 'first-dose priority' strategy averted 81% [IQR:75%–86] of potential mpox cases. Their 'first-dose priority' strategy was more effective than alternatives, averting 3.0% [IQR:1.2%–4.5%] more cases than the 'intermediate' strategy, and 9.5% [IQR:7.7%–12%] more cases than the 'second-dose priority' strategy.

Conclusions: A focus on widespread, 1 dose vaccination during future mpox outbreaks can reduce cases and limit transmission in scenarios of limited vaccine supply, limited vaccine administration capacity, or increased demand.

Introduction

Over 30,000 individuals in the United States were diagnosed with mpox in 2022, with 33% of these cases occurring in May through July, and daily cases peaking on August 1st. Official CDC guidance was to administer two doses of the JYNNEOS® vaccine 4 weeks apart to priority populations (primarily gay, bisexual, and other men who have sex with men, hereafter referred to as MSM, with multiple recent sexual partners) [1]. During this period of rapidly increasing daily cases, demand for vaccination exceeded available doses of the JYNNEOS® vaccine and the capacity for administration in many jurisdictions. Given the rapidly increasing number of cases in New York City (NYC) and the resultant need to protect priority populations as quickly as possible, NYC focused their vaccination campaign on widespread, 1 dose vaccination, (a 'first-dose priority' strategy), with plans to administer second doses when supply and demand allowed, rather than following official CDC recommendations, which would have resulted in earlier 2 dose vaccination in a narrower portion of the population. Due to the urgency of the outbreak, NYC Health was required to make this decision with limited data on the effectiveness of 2 dose vs. 1 dose vaccination.

Understanding the relative impact of prioritizing 2-dose vaccination in a relatively narrow portion of the population (referred to as narrow, 2 dose vaccination) compared to a 'first-dose priority' strategy (referred to as widespread, 1 dose vaccination) may inform vaccination strategies in potential future mpox outbreaks [2]. We used vaccine administration and case report data from NYC to calibrate a dynamic network model of sexually transmitted monkeypox virus infection among MSM. We then estimated the number of mpox cases averted by vaccine administration in NYC over one year. We further estimated the effectiveness of strategies that focused on administering single doses of the vaccine to a widespread portion of the eligible population, as happened in NYC (the "first-dose priority" strategy), compared to an

administration strategy of pre-allocating a full course of doses to a narrow portion of the eligible

population (the "second-dose priority" strategy), as well as a vaccine strategy of not pre-

allocating doses, but choosing to administer vaccines to those eligible for a second dose ahead of

completely unvaccinated individuals (the "intermediate" strategy).

Methods

We used a previously described dynamic network model of sexually associated

monkeypox virus transmission in MSM [2–4], with parameters updated based on nationally

distributed surveys of sexual behavior among MSM from 2017-2019 (the ARTnet study) [5].

This model simulates the 167,000 MSM living in NYC, and a changing network of sexual

partnerships between them. We model three types of sexual partnerships: individuals in our

model can have 0 or 1 'Main' partners (defined as enduring sexual partners who took priority

over others), between 0 and 3 'Casual partners' (defined as enduring sexual partners besides the

main partner), and 0 or 1 'one-time' partners per timestep (defined as partners without repeat

sexual contact). For each timestep in the model, enduring partnerships have a probability of

forming and dissolving, and individuals have a probability of engaging in one-time partnerships

based on their assignment to one of 6 sexual activity groups, with activity group 1 representing

the lowest sexual activity level (never engaging in one-time partnerships) and activity group 6

representing the highest sexual activity level (30% chance of engaging in a one-time partnership

per day). All network parameters can be found in Table S1.

We used an SEIR (susceptible, exposed, infectious, resistant) natural history in our

model, expanded to account for pre-symptomatic transmission and multi-dose vaccination [6].

Individuals start in the susceptible (S) class. An infectious individual has a probability of

infecting a susceptible partner given by the probability of sexual contact per timestep multiplied

by the probability of infection per sexual exposure (μ). Upon acquiring infection, individuals

enter a pre-symptomatic non-infectious state (E), after which they have a probability per day of

entering the pre-symptomatic and infectious state (P), then the symptomatic and infectious state

(I), and finally the recovered and resistant state (R). Individuals can also be vaccinated with 1

($V1$) or 2 ($V2$) doses of the vaccine, with effects described below. Symptom onset reduces sexual

contact rate with 'main' and 'casual' partners by 50% and causes individuals to move to one

lower sexual activity level until they recover. A proportion of individuals, (ρ), will test for mpox

γ days after they develop symptoms, with γ based on the date-varying time between reported

symptom onset and mpox tests in case data. After a positive mpox test, individuals become

aware of their infection status, and no longer transmit the virus through sexual activity.

Individuals who learn their infection status sustain contact with their 'main' partner such that

they have a 10% chance of infecting their 'main' partner over the duration of the infection,

reflecting prior estimates of household transmission [7]. Infected individuals who seek medical

care are reported as diagnosed cases, hereafter referred to as *cases*.

We initiated the model by introducing 5 newly exposed individuals into the two highest

sexual activity groups on May 14th. This produced a median of 5 cumulative cases in the model

on May 31st, matching case data from NYC.

Our network does not account for potential periods of increased sexual activity associated

with the high frequency of MSM gatherings (e.g., pride festivals) throughout the summer.

Additionally, we assume that importation of mpox cases from countries impacted by mpox prior

to the outbreak in the United States may have fed the initial surge of mpox cases. Thus, we

model a 'surge period' during which we randomly select individuals in the top two sexual

activity groups to enter the E state via 'extra-network' contacts at a rate fit to incident case report

data (see fitting procedure below). We set this surge period to occur in the two weeks after NYC

Pride (June 26th – July 10th) but note that there were many MSM oriented gatherings in NYC at

this time and are not assuming that a disproportionate level of exposures happened at any

specific event.

Over the course of each simulation, individuals decrease their probability of one-time

partnerships and their rate of sexual contact with casual partners as a function of perceived risk

of mpox [8]. We parameterize this perceived risk based on frequency of mpox discussion on

online LGBT+ discussion forums over time, as discussed by Clay et al. [4], and fit the magnitude

of this behavioral adaptation to incident case report data (see fitting procedure below).

Vaccination

We ran three vaccination scenarios (Figure 1). We first ran a scenario where first and

second doses administered per week matched those reported by NYC through March 18, 2023.

This scenario is our baseline 'first-dose priority' strategy, as prioritizing widespread, 1 dose

vaccination was the goal of NYC's vaccination campaign. We then ran a counterfactual scenario

where the total doses administered per week matched those in our 'first-dose priority' strategy,

but during each timestep, doses were always administered first to individuals who were due for a

second dose, and first doses were only given once there were no individuals waiting for a second

dose ('intermediate' strategy). Finally, we ran an additional counterfactual scenario where

individuals receiving their first dose were pre-allocated a second dose to be administered five

weeks later, reflecting average time between doses in other jurisdictions (appendix). Thus, every

individual completed their course on time, but total dose administration was slowed ('second-

dose priority' strategy). The cumulative number of cases averted by vaccine administration was

calculated as the cumulative number of cases in the 'no vaccination' scenario minus the

cumulative cases in a scenario with vaccine administration. We compared the number of cases

averted by the baseline scenario to the number of cases averted by the counterfactual vaccination

scenarios.

While MSM, transgender, gender non-conforming and non-binary adults (TGNCNB)

with multiple sexual partners were all initially eligible for mpox vaccination, we only model

MSM due to availability of sexual network data [5]. According to a 2020 citywide population-

based survey, MSM made up 82% of MSM and TGNCNB adults in NYC with 2+ sexual

partners over a 12-month period [9]. Thus, we assume that 82% of mpox vaccines administered

in NYC were administered to MSM in our model.

As vaccines were originally intended for selected groups, including individuals with

multiple recent sexual partners [10], we only vaccinate individuals in the top two sexual activity

groups for the first four weeks of vaccination, only vaccinate individuals in the top four sexual

activity groups for the next four weeks of vaccination, and only vaccinate individuals with a non-

zero probability of engaging in one-time sexual partnerships for the rest of the simulation. In our

model, susceptible (S) and pre-symptomatic (E, P) individuals are eligible for vaccination.

However, vaccination does not prevent individuals in the E or P class from becoming infectious.

Individuals are eligible for second doses of the vaccine if they have received their first dose at

least four weeks in the past. In the case of breakthrough infections (i.e. infections of vaccinated

individuals), we assume these individuals enter the pre-symptomatic (E) class, i.e., prior

vaccination has no effects on subsequent contagiousness or pathogenicity.

CDC recently published JYNNEOS® effectiveness estimates (the overall reduction in

infection risk for a vaccinated individual compared to an unvaccinated individual over an

observed period) of 75.2% for one dose, and 85.9% for two doses [11]. We use these values in

our model as per-exposure reductions in transmission probability due to vaccination, hereafter

referred to as per-exposure vaccine efficacy. Setting vaccine effectiveness equal to per-exposure

vaccine efficacy requires the assumption that individuals in the vaccine effectiveness study were

not exposed to mpox multiple times (Figure S2). If individuals in the vaccine effectiveness study

were exposed to mpox multiple times, we would expect for per-exposure vaccine efficacy to be

greater than vaccine effectiveness. We thus repeated our analysis while increasing per-exposure

vaccine efficacy by 10% and found no qualitative difference in our results (Figures S4-6). In all

scenarios, we assume that doses become effective two weeks after administration.

Fitting Process

Our model has three free parameters whose values were informed via fitting: (1) the

probability of transmission per exposure ('transmission probability', μ), (2) the number of

additional individuals infected per day by extra-network contacts during the 'surge period'

('surge exposures', ε), and (3) the maximum percent reduction in probability of one-time or

casual sexual contact per day in response to perceived risk of mpox ('behavioral adaptation', ω).

We fit these parameters to incident daily cases in NYC using a 5-step process.

First, we used Latin Hypercube Sampling (LHS) to generate 1,000 unique parameter sets,

sampling between 40% and 100% transmission probability, between 100 and 1,000 surge

exposures, and between 0% and 60% behavioral adaptation. Prior studies used transmission

probability values below our minimum [12], but these lower values were based off estimates of

household, rather than sexual, transmission, and do not generate sustained transmission in our

network.

Second, we simulated a single run of outbreak dynamics under the baseline 'first-dose

priority' strategy employed by NYC for each LHS-generated parameter set from May 14, 2022

to January 18, 2023 (250 simulated days). Third, we filtered out parameter sets which predicted a

final cumulative case incidence outside of that observed in NYC +/- 50%. Fourth, for each

remaining parameter set, we calculated the likelihood that the simulated number of incident daily

cases could generate the observed number of incident daily cases through Jan 18 using a negative

binomial probability distribution. Finally, we drew 100 parameter sets (with replacement) with

the calculated likelihood used as the relative draw probability for each parameter set. These 100

drawn parameter sets represent the posterior distributions of our fit parameters.

For each of these 100 parameter sets, we ran each of our vaccine model scenarios (Figure

1) from May 14, 2022 to May 14, 2023 and compared median and interquartile ranges of

cumulative cases over time for each vaccine administration strategy. We additionally ran a third

counterfactual model scenario where no vaccines were administered to measure the total percent

of cases averted by vaccination compared to the 'first-dose priority' strategy (baseline model).

Results

Our fitting procedure selected for a transmission probability of 59% [IQR: 55% – 65%],

440 surge exposures [IQR: 280 – 560], and behavioral adaptation of 37% [IQR: 26% – 47%]

(Figure 2, Table 2). The posteriors of transmission probability and behavioral adaptation are both

correlated with surge exposures (Figure S3). Thus, these parameter estimates should not be used

in other contexts.

Our model estimates that there would have been 17,800 cumulative cases [IQR: 13,000 –

25,900] by May 14, 2023 in the counterfactual scenario with no vaccination. Our model further

estimates that the baseline 'first-dose priority' strategy averted 81% [IQR: 75% − 86%] of these

cases (Figure 3).

Taking the difference in cases averted across all parameter sets, we estimate that

compared to the baseline 'first-dose priority' strategy employed by NYC, the counterfactual

'intermediate' strategy would have averted 3.0% [IQR: 1.2% − 4.5%] fewer cases, and the

counterfactual 'second-dose priority' strategy would have averted 9.5% [IQR: 7.7% − 12%]

fewer cases (Figure 4A). This would result in up to 2,000 fewer cases averted had NYC chosen

an alternative vaccine administration strategy. This result is driven by exposure heterogeneity

and incremental dose efficacy. In our model, the first individuals vaccinated have a one-time

partner acquisition rate 250 times greater than individuals vaccinated later in the outbreak (Table

S1), which favors narrow, 2 dose vaccination of individuals with higher sexual activity.

However, this exposure heterogeneity is overwhelmed by the second vaccine dose adding

relatively little incremental protection (10.7%) compared to the first dose (75.2%), which favors

widespread, 1 dose vaccination.

NYC was allocated a relatively high number of JYNNEOS doses per high priority

individual compared to many other jurisdictions. Thus, we conducted additional analyses,

reducing doses administered in the NYC model by 75% to estimate whether the optimal vaccine

administration strategy would differ if NYC had been allocated fewer doses. We found that in

this scenario, the baseline 'first-dose priority' strategy was even more superior, averting 43%

[IQR: 39% − 48%] of cases, while the counterfactual 'intermediate' strategy averted 11% [IQR:

2.0% − 18%] fewer cases, and the counterfactual 'second-dose priority' strategy averted 25%

[IQR: 13% − 34%] fewer cases than the 'first-dose priority' strategy (Figure 4B).

In addition to incremental dose efficacy and heterogeneity in exposure probabilities, the

overall transmissibility of a pathogen will influence whether widespread, 1 dose vaccination or

narrow, 2 dose vaccination is favored. When we increase per-exposure vaccine efficacy

(appendix S.5), our fitting procedure selected parameter sets with higher monkeypox virus

transmissibility, increasing cumulative cases in the no-vaccine scenario by 8.2% (Figure 2 vs.

Figure S5). Because most transmission events in our model happen among high-activity

individuals, in this higher transmissibility scenario, high activity individuals may need more per-

exposure protection to reduce the effective growth rate of mpox to below 1. This favors narrow,

2 dose vaccination strategies more than our primary analysis (Figure 2), resulting in all vaccine

administration strategies averting similar numbers of cases (Figure S6).

Discussion

During the 2022 mpox outbreak, demand for vaccines initially outstripped supply,

preventing 2 dose vaccination for the total population likely to benefit from vaccination. Thus,

NYC prioritized administration of first doses to reach a larger portion of the impacted population

as quickly as possible. In this analysis, we modeled the strategy focusing on widespread, 1 dose

vaccination employed by NYC, compared to counterfactual strategies focusing on 2 dose

vaccination in narrower portions of the population. We estimated that the NYC vaccine rollout

prevented 81% of potential mpox cases. We further estimated that NYC's strategy of prioritizing

widespread, 1 dose vaccination (the 'first-dose priority' strategy) averted more cases than

alternative strategies prioritizing narrow, 2 dose vaccination, and would also have been the

superior strategy had vaccine supply been even more limited.

Increasing vaccine coverage will decrease the probability of future mpox outbreaks and

decrease the size of outbreaks if they occur [2]. CDC estimates that a vaccination threshold of

50% among priority populations (HIV PrEP indicated MSM and MSM living with HIV) would

prevent monkeypox virus transmission [2]. However, 70% of analyzed jurisdictions, including

urban centers with large MSM populations, are currently below this thresholds, with 34% of

analyzed jurisdictions having vaccinated 25% or less of the priority population [2]. Thus, CDC

recommends the continued vaccination of priority populations to prevent future mpox outbreaks

[13]. Currently, vaccine availability outstrips demand among priority populations, and state and

local health departments do not need to decide whether to prioritize narrow, 2 dose vaccination

or widespread, 1 dose vaccination. Rather, state and local health departments can focus both on

initiating the vaccine series for those in priority population who remain unvaccinated or have

recently entered the priority population, followed by completion of the 2 dose vaccine series.

Completing the vaccine series is important as the duration of effectiveness of a single dose is not

known.

Given the potential for mpox resurgence as well as for mpox to spread to populations not

previously impacted by mpox, demand for mpox vaccines could increase, potentially exceeding

vaccine supply or vaccination capacity. In either situation, local and state health departments

may consider whether to focus on prioritizing narrow, 2 dose vaccination, or widespread, 1 dose

vaccination. Our analysis shows that in NYC, prioritizing widespread, 1 dose vaccination averted

the greatest number of cases, making it the superior strategy, though it may be equivalent to

other strategies if we are underestimating per-exposure vaccine efficacy. Even if all strategies

were equivalent in averting cases, prioritizing widespread, 1 dose vaccination has the benefit of

improving vaccine equity. In recent vaccine rollouts, groups who have historically faced

systematic barriers to accessing healthcare received a disproportionally small number of initial

vaccine doses [14]. Narrow, 2 dose vaccination strategies, which focus on concentrating all

vaccine doses in a smaller number of individuals who access vaccine doses first, may thus

exacerbate health inequities. This is particularly problematic as individuals are most likely to

have close sexual contact with individuals of the same race or socioeconomic status [15].

Narrow, 2 dose strategies may thus lead to uncontrolled transmission in groups already facing a

disproportionate burden of most health problems, exacerbating health disparities.

Vaccination can yield greater health benefits when the selection of vaccine administration

strategies takes into account heterogeneity in immune function, which may in turn generate

heterogeneity in both individual susceptibility and vaccine effectiveness. People with HIV

(PWH) make up 19% of MSM [16,17], but 55% of mpox cases in the United States with known

and recorded HIV status. The disproportionate representation of PWH among mpox cases may

be caused by (a) PWH having a higher probability of mpox exposure, (b) PWH having a greater

susceptibility to monkeypox virus infection, or (c) PWH being more likely to experience mpox

symptoms when infected, given that coinfection between HIV and mpox can lead to severe, life-

threatening outcomes in individuals not receiving antiretroviral therapy and who had low CD4

counts [18]. JYNNEOS® vaccination has reduced efficacy in individuals living with

immunocompromising conditions, including uncontrolled HIV, with a reduction in first-dose

effectiveness of 21.1%, and a reduction of second-dose effectiveness of 17.6%. Further, the

incremental effectiveness of second dose vaccination is higher in people living with

immunocompromising conditions than in others, with second dose vaccination increasing

effectiveness by 20.8 percentage points, compared to 10.7 percentage points. Thus, because

PWH may be more likely to acquire mpox, are more likely to experience severe symptoms, and

benefit more from receiving a second vaccine dose than others, future vaccination strategies may

benefit from giving PWH 2 dose vaccine courses as quickly as possible, even if the larger

vaccine strategy is for widespread, 1 dose vaccination. This strategy could be paired with further

efforts to connect people living with uncontrolled HIV to HIV services, given that increased

CD4 counts may increase vaccine efficacy and reduce severity of mpox.

Choosing whether to prioritize completion of a multi-dose course in a narrow portion of

the population at high likelihood of infection, versus widespread, 1 dose vaccination will arise in

future outbreaks of other diseases, whenever vaccination involves multiple doses [19]. When

choosing between vaccination strategies during an outbreak, public health agencies need to be

quick, flexible, and make decisions with limited data. Mathematical modelers can conduct

studies now, before those outbreaks occur, that will allow public health officials to make

informed decisions during the initial stages of an outbreak. The optimal vaccine strategy in an

outbreak will depend on multiple factors, including the incremental effectiveness of first vs.

second doses, the population contact network, vaccine administration capacity, and the epidemic

growth rate. Modeling studies can explore how these parameters shift the optimal vaccination

strategy, while connecting these parameters to pre-existing data (e.g., the population contact

network), or data that can be easily collected in the early stages of an outbreak (e.g. epidemic

growth rate). Results from these studies can inform decisions for public health officials, leading

to quick, evidence-based public health leadership.

307 Acknowledgments

308   The findings and conclusions in this report are those of the authors and do not necessarily

309 represent the views of the Centers for Disease Control and Prevention or the National Cancer

310 Institute. We would like to thank Dr. Jennifer Rosen for her support.

Bibliography

313   1.   JYNNEOS Vaccine | Mpox | Poxvirus | CDC [Internet]. [cited 2023 May 17]. Available

314   from: https://www.cdc.gov/poxvirus/mpox/interim-considerations/jynneos-vaccine.html

315   2.   Pollock ED, Clay PA, Keen A, et al. Potential for Recurrent Mpox Outbreaks Among

316   Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2023. MMWR

317   Morb Mortal Wkly Rep [Internet]. **2023** [cited 2023 May 26]; 72(21):568–573. Available

318   from: https://www.cdc.gov/mmwr/volumes/72/wr/mm7221a1.htm

319   3.   Spicknall IH, Pollock ED, Clay PA, et al. Modeling the impact of sexual networks in the

320   transmission of Monkeypox virus among gay, bisexual, and other men who have sex with

321   men — United States, 2022 [Internet]. 2022 [cited 2022 Oct 25]. Available from:

322   https://stacks.cdc.gov/view/cdc/120698

323   4.   Clay PA, Asher JM, Carnes N, et al. Modelling the impact of vaccination and sexual

324   behavior change on reported cases of mpox in Washington D.C. medRxiv [Internet]. Cold

325   Spring Harbor Laboratory Press; **2023** [cited 2023 May 17]; :2023.02.10.23285772.

326   Available from: https://www.medrxiv.org/content/10.1101/2023.02.10.23285772v1

327   5.   Weiss KM, Goodreau SM, Morris M, et al. Egocentric sexual networks of men who have

328   sex with men in the United States: Results from the ARTnet study. Epidemics. Elsevier;

329   **2020**; 30:100386.

330   6.   Brosius I, Dijck C Van, Coppens J, et al. Presymptomatic viral shedding in high-risk

331   mpox contacts: A prospective cohort study. J Med Virol [Internet]. John Wiley & Sons,

332   Ltd; **2023** [cited 2023 May 17]; 95(5):e28769. Available from:

333   https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28769

7.   Beer EM, Bhargavi Rao V. A systematic review of the epidemiology of human

monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis

[Internet]. Public Library of Science; **2019** [cited 2023 Jan 27]; 13(10):e0007791.

Available from:

https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007791

8.   Delaney KP, Sanchez T, Hannah M, et al. Strategies Adopted by Gay, Bisexual, and Other

Men Who Have Sex with Men to Prevent Monkeypox virus Transmission — United

States, August 2022. MMWR Morb Mortal Wkly Rep [Internet]. Centers for Disease

Control MMWR Office; **2022** [cited 2022 Oct 25]; 71(35). Available from:

https://www.cdc.gov/mmwr/volumes/71/wr/mm7135e1.htm

9.   New York City Department of Health and Mental Hygeine. EpiQuery - Community

Health Survey 2020 [Internet]. [cited 2023 Aug 4]. Available from: https://a816-

health.nyc.gov/hdi/epiquery/visualizations?PageType=ps&PopulationSource=CHS

10.   FACT SHEET: Biden-Harris Administration's Monkeypox Outbreak Response | The

White House [Internet]. [cited 2022 Nov 1]. Available from:

https://www.whitehouse.gov/briefing-room/statements-releases/2022/06/28/fact-sheet-

biden-harris-administrations-monkeypox-outbreak-response/

11.   Dalton AF, Diallo AO, Chard AN, et al. Estimated Effectiveness of JYNNEOS Vaccine in

Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19,

2022–March 31, 2023. MMWR Morb Mortal Wkly Rep [Internet]. **2023** [cited 2023 May

23]; 72(20):553–558. Available from:

https://www.cdc.gov/mmwr/volumes/72/wr/mm7220a3.htm

12.   Endo A, Murayama H, Abbott S, et al. Heavy-tailed sexual contact networks and

monkeypox epidemiology in the global outbreak, 2022. Science (80-) [Internet].

American Association for the Advancement of Science; **2022** [cited 2023 Jan 27];

378(6615). Available from: https://www.science.org/doi/10.1126/science.add4507

13.   Vaccination | Mpox | Poxvirus | CDC [Internet]. [cited 2023 May 26]. Available from:

https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html

14.   Baack BN, Abad N, Yankey D, et al. COVID-19 Vaccination Coverage and Intent Among

Adults Aged 18–39 Years — United States, March–May 2021. Morb Mortal Wkly Rep

[Internet]. Centers for Disease Control and Prevention; **2021** [cited 2023 May 26];

70(25):928. Available from: /pmc/articles/PMC8224866/

15.   Hernández-Romieu AC, Sullivan PS, Rothenberg R, et al. Heterogeneity of HIV

prevalence among the sexual networks of Black and White MSM in Atlanta: illuminating

a mechanism for increased HIV risk for young Black MSM. Sex Transm Dis [Internet].

NIH Public Access; **2015** [cited 2022 Oct 26]; 42(9):505. Available from:

/pmc/articles/PMC4536576/

16.   Linley L, Johnson AS, Song R, et al. Estimated HIV incidence and prevalence in the

United States 2010–2019 [Internet]. 2021 [cited 2023 May 18]. Available from:

https://stacks.cdc.gov/view/cdc/112160

17.   Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the Population Sizes of Men Who

Have Sex With Men in US States and Counties Using Data From the American

Community Survey. JMIR Public Heal Surveill 2016;2(1)e14

https//publichealth.jmir.org/2016/1/e14 [Internet]. JMIR Public Health and Surveillance;

2016 [cited 2022 Oct 31]; 2(1):e5365. Available from:

https://publichealth.jmir.org/2016/1/e14

18.   Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a

global case series. Lancet. Elsevier; **2023**; 401(10380):939–949.

19.   Adult Immunization Schedule – Healthcare Providers | CDC [Internet]. [cited 2023 May

19]. Available from: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

20.   Aral SO, Blanchard JF. The Program Science initiative: improving the planning,

implementation and evaluation of HIV/STI prevention programs. Sex Transm Infect

[Internet]. BMJ Publishing Group Ltd; **2012** [cited 2023 Aug 1]; 88(3):157–159.

Available from: https://sti.bmj.com/content/88/3/157

21.   Charniga K, Masters NB, Slayton RB, et al. Estimating the incubation period of

monkeypox virus during the 2022 multi-national outbreak. medRxiv [Internet]. Cold

Spring Harbor Laboratory Press; **2022** [cited 2023 May 17]; :2022.06.22.22276713.

Available from: https://www.medrxiv.org/content/10.1101/2022.06.22.22276713v2

22.   Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: the case

for screening. Prev Med (Baltim). Academic Press; **2003**; 36(4):502–509.

23.   Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of Gonorrhea and Chlamydia

Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who

Have Sex With Men: A Modeling Study. Clin Infect Dis [Internet]. Oxford Academic;

2017 [cited 2023 Feb 16]; 65(5):712–718. Available from:

https://academic.oup.com/cid/article/65/5/712/3824878

Table 1: Model parameters. Values given as a range represent priors of parameters fit to data.

Parameter Description	Value	Source
Initial Conditions		
Population size	167,000	EpiQuery - Community Health Survey 2020: NYC Department of Health and Mental Hygeine.
Initial number infectious individuals	5	Model Assumption
Date seeded with initial infections	May 14th	Selected to align date of 5 cases in median model output and case reports
Surge Exposures (Number individuals infected from June 26 – July 10, a period of large gatherings of gay, bisexual, and other men who have sex with men)	[100 – 1000]	Fit to case report data
Natural History Parameters		
Transmission Probability (Probability of transmission per sexual contact)	[40% – 100%]	Fit to case report data

Mean duration of post-exposure, pre-symptomatic period	7.6 days	Charniga K, Masters NB, Slayton RB, et al. Estimating the incubation period of monkeypox virus during the 2022 multi-national outbreak. medRxiv. **2022**
Mean duration of pre-symptomatic infectious period	4 days	Brosius I, Dijck C Van, Coppens J, et al. Presymptomatic viral shedding in high-risk mpox contacts: A prospective cohort study. J Med Virol [Internet]. **2023**
Mean duration of infectious period	27 days	Spicknall IH, Pollock ED, Clay PA, et al. Modeling the impact of sexual networks in the transmission of Monkeypox virus among gay, bisexual, and other men who have sex with men — United States, 2022. MMWR. **2022**
Treatment Seeking and Vaccine Parameters		

Probability of seeking treatment	0.8	Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: the case for screening. Prev Med. **2003**
Duration of infectious period if seeking treatment (time until medical attention post-symptoms)	15 days on first day of simulation, linearly decreases to 5.0 days on day 42 of simulation, stays at 5.0 days for rest of simulation.	Case Report Data
First dose per-exposure vaccine efficacy	75.2% (85% in sensitivity analysis)	Dalton AF, Diallo AO, Chard AN, et al. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022– March 31, 2023. MMWR. **2023**
Second dose per-exposure vaccine efficacy	85.9% (95% in sensitivity analysis)	
Minimum time between first and second dose	28 days	JYNNEOS Vaccine	Mpox	Poxvirus	CDC [Internet].
Behavior Change Parameters		

Behavioral Adaptation (Maximum percent reduction in daily probability of forming one-time sexual partnerships.)	[0% – 60%]	Fit to case report data

402   Table 2: Posterior values of parameters fit to incident cases.

Parameter	Median	1st quartile	3rd Quartile
Surge Exposures (Number individuals infected from June 26 – July 10, a period of large gatherings of gay, bisexual, and men who have sex with men)	440	280	560
Transmission Probability (Probability of transmission per sexual contact)	59%	55%	65%
Behavioral Adaptation (Maximum percent reduction in daily probability of forming one-time sexual partnerships.)	37%	26%	47%

Figure 1: Allocation of doses over time for each vaccine administration strategy[*]. Y-axis shows

number of doses given over time on the X-axis. Top two panels indicate number of first and

second doses given, respectively, for each vaccine administration strategy while bottom panel

indicates the sum of first and second doses given for each vaccine administration strategy. Colors

indicate different vaccine administration strategies.

[*]First-dose priority: first and second doses in model are based on first and second doses administered by

NYC. Intermediate: Individuals who are eligible for a second dose receive priority for available doses, but

there is no preallocation. Second-dose priority: doses are preallocated to ensure that all individuals

receive full course of thes vaccine.

Figure 2: Mpox model fit to data. Dots indicate the 1 week running mean of incident daily cases

in NYC, used as our fitting target. Blue line in represents median incident daily cases of model

runs from the 100 parameter sets selected in our fitting procedure, with band representing

interquartile range of model runs, assuming a 'first-dose priority' strategy. Labels indicate the

beginning of pre-exposure vaccination on June 26th, peak administration of first doses, occurring

the week of August 7th, and peak administration of second doses, occurring the week of

September 18th.

Figure 3: Estimated cumulative cases over a year under the 'first-dose priority' strategy

employed by NYC compared to a 'no vaccination' scenario. Lines represent median cumulative

cases of model runs from the 100 parameter sets selected in our fitting procedure, with bands

representing interquartile ranges of model runs.

Figure 4: Comparison of different vaccine administration strategies[*]. We show the difference in

cases under the 'intermediate' or 'second-dose priority' strategy compared to the 'first-dose

priority' strategy on the Y-axis, over time on the X-axis. Solid lines indicate median values

across fit parameter sets, and transparent bands indicate interquartile ranges across parameter

sets. Panel A uses vaccine administration numbers shown in Figure 1, while panel B cuts doses

given by 75% to emulate jurisdictions with lower dose availability.

[*]First-dose priority: first and second doses in model are based on first and second doses administered by

NYC. Intermediate: Individuals who are eligible for a second dose receive priority for available doses, but

there is no preallocation. Second-dose priority: doses are preallocated to ensure that all individuals

receive full course of thes vaccine.